TNFRSF13C and atherosclerosis: Anti-BAFFR antibody treatment of atherosclerotic ApoE−/− mice indicated attenuated progression of atherosclerosis, with reductions in atherosclerotic lesions, by 30% (total lesion size), 33% in oil red-O stained lipid accumulation and 35% in CD68+ macrophage accumulation ([P<0.05]; Figures 6F–G).